Patient characteristics and outcomes
| Characteristic/category . | n . | Count (%) . |
|---|---|---|
| Study site | 575 | |
| Fred Hutchinson Cancer Research Center | 253 (44%) | |
| University of Minnesota | 61 (11%) | |
| Dana-Farber Cancer institute | 65 (11%) | |
| Stanford University Medical Center | 74 (13%) | |
| Vanderbilt University Medical Center | 48 (8%) | |
| Medical College of Wisconsin | 23 (4%) | |
| Washington University Medical Center | 4 (1%) | |
| Moffitt Cancer Center | 39 (7%) | |
| Memorial Sloan Kettering Cancer Center | 8 (1%) | |
| Case type | 575 | |
| Incident | 342 (59%) | |
| Prevalent | 233 (41%) | |
| Patient age at registration (y), median (range) | 575 | 52 (19-79) |
| Patient gender | 575 | |
| Female | 242 (42%) | |
| Male | 333 (58%) | |
| Diagnosis | 575 | |
| AML | 193 (34%) | |
| ALL | 62 (11%) | |
| CML | 30 (5%) | |
| CLL | 46 (8%) | |
| MDS | 89 (15%) | |
| NHL | 85 (15%) | |
| HL | 17 (3%) | |
| MM | 29 (5%) | |
| AA | 6 (1%) | |
| Other | 18 (3%) | |
| Disease status | 571 | |
| Early | 184 (32%) | |
| Intermediate | 248 (43%) | |
| Advanced | 139 (24%) | |
| Transplant source | 575 | |
| Bone marrow | 40 (7%) | |
| Cord blood | 28 (5%) | |
| Peripheral blood | 507 (88%) | |
| Transplant type | 571 | |
| Myeloablative | 297 (52%) | |
| Nonmyeloablative | 274 (48%) | |
| Donor-patient CMV status | 569 | |
| Patient and donor CMV both negative | 192 (34%) | |
| Patient or donor CMV positive | 377 (66%) | |
| Donor-patient gender combination | 569 | |
| Female into male | 167 (29%) | |
| Others | 402 (71%) | |
| Donor match | 573 | |
| Matched related | 238 (42%) | |
| Matched unrelated | 244 (43%) | |
| Mismatched | 91 (16%) | |
| Prior grade 2-4 acute GVHD | 575 | |
| Yes | 311 (54%) | |
| No | 264 (46%) | |
| 2005 NIH chronic GVHD global severity score | 575 | |
| Mild or less | 53 (9%) | |
| Moderate | 302 (53%) | |
| Severe | 220 (38%) |
| Characteristic/category . | n . | Count (%) . |
|---|---|---|
| Study site | 575 | |
| Fred Hutchinson Cancer Research Center | 253 (44%) | |
| University of Minnesota | 61 (11%) | |
| Dana-Farber Cancer institute | 65 (11%) | |
| Stanford University Medical Center | 74 (13%) | |
| Vanderbilt University Medical Center | 48 (8%) | |
| Medical College of Wisconsin | 23 (4%) | |
| Washington University Medical Center | 4 (1%) | |
| Moffitt Cancer Center | 39 (7%) | |
| Memorial Sloan Kettering Cancer Center | 8 (1%) | |
| Case type | 575 | |
| Incident | 342 (59%) | |
| Prevalent | 233 (41%) | |
| Patient age at registration (y), median (range) | 575 | 52 (19-79) |
| Patient gender | 575 | |
| Female | 242 (42%) | |
| Male | 333 (58%) | |
| Diagnosis | 575 | |
| AML | 193 (34%) | |
| ALL | 62 (11%) | |
| CML | 30 (5%) | |
| CLL | 46 (8%) | |
| MDS | 89 (15%) | |
| NHL | 85 (15%) | |
| HL | 17 (3%) | |
| MM | 29 (5%) | |
| AA | 6 (1%) | |
| Other | 18 (3%) | |
| Disease status | 571 | |
| Early | 184 (32%) | |
| Intermediate | 248 (43%) | |
| Advanced | 139 (24%) | |
| Transplant source | 575 | |
| Bone marrow | 40 (7%) | |
| Cord blood | 28 (5%) | |
| Peripheral blood | 507 (88%) | |
| Transplant type | 571 | |
| Myeloablative | 297 (52%) | |
| Nonmyeloablative | 274 (48%) | |
| Donor-patient CMV status | 569 | |
| Patient and donor CMV both negative | 192 (34%) | |
| Patient or donor CMV positive | 377 (66%) | |
| Donor-patient gender combination | 569 | |
| Female into male | 167 (29%) | |
| Others | 402 (71%) | |
| Donor match | 573 | |
| Matched related | 238 (42%) | |
| Matched unrelated | 244 (43%) | |
| Mismatched | 91 (16%) | |
| Prior grade 2-4 acute GVHD | 575 | |
| Yes | 311 (54%) | |
| No | 264 (46%) | |
| 2005 NIH chronic GVHD global severity score | 575 | |
| Mild or less | 53 (9%) | |
| Moderate | 302 (53%) | |
| Severe | 220 (38%) |
| . | . | Estimate (95% CI) . |
|---|---|---|
| FFS | ||
| At 1 y after enrollment | 45% (41%-49%) | |
| At 2 y after enrollment | 29% (25%-33%) | |
| At 4 y after enrollment | 11% (4%-22%) | |
| Relapse | ||
| At 1 y after enrollment | 6% (4%-8%) | |
| At 2 y after enrollment | 10% (8%-13%) | |
| At 4 y after enrollment | 13% (10%-17%) | |
| NRM | ||
| At 1 y after enrollment | 4% (3%-6%) | |
| At 2 y after enrollment | 6% (4%-8%) | |
| At 4 y after enrollment | 14% (7%-27%) | |
| Survival | ||
| At 1 y after enrollment | 89% (86%-91%) | |
| At 2 y after enrollment | 81% (78%-85%) | |
| At 4 y after enrollment | 71% (66%-76%) |
| . | . | Estimate (95% CI) . |
|---|---|---|
| FFS | ||
| At 1 y after enrollment | 45% (41%-49%) | |
| At 2 y after enrollment | 29% (25%-33%) | |
| At 4 y after enrollment | 11% (4%-22%) | |
| Relapse | ||
| At 1 y after enrollment | 6% (4%-8%) | |
| At 2 y after enrollment | 10% (8%-13%) | |
| At 4 y after enrollment | 13% (10%-17%) | |
| NRM | ||
| At 1 y after enrollment | 4% (3%-6%) | |
| At 2 y after enrollment | 6% (4%-8%) | |
| At 4 y after enrollment | 14% (7%-27%) | |
| Survival | ||
| At 1 y after enrollment | 89% (86%-91%) | |
| At 2 y after enrollment | 81% (78%-85%) | |
| At 4 y after enrollment | 71% (66%-76%) |
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma.